Exploring the Efficacy of Dukravicitinib in Lupus Skin Diseases

The chapter delves into a study evaluating the efficacy of Dukravicitinib in managing chronic skin conditions linked to lupus, examining various drug doses and specific skin responses over 48 weeks using Class C criteria. It also considers the complexities of employing composite indices in lupus clinical trials and the feasibility of utilizing organ-specific endpoints such as skin reactions to assess the drug's effectiveness.